For healthcare professionals only
You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.
This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.
Study participants were insulin-naïve patients with type 2 diabetes. Concomitant glucose-lowering agents were permitted from baseline throughout the study periods. In ONWARDS 1, sulphonylureas and glinides were discontinued at randomisation. In ONWARDS 3, sulphonylureas and glinides, if used, were reduced by 50% at randomisation at the investigator’s discretion. A similar proportion of patients, 175 of 984 and 112 of 588 (18% and 19%), were treated with GLP-1 RAs in the glargine U100 and degludec comparisons, respectively.2,3
*Clinically significant hypoglycaemia is defined as a blood glucose level <54 mg/dL, confirmed with a blood glucose meter. Severe hypoglycaemia is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.2,3
†Clinically significant or severe hypoglycaemia in the preceding 12 weeks in ONWARDS 1: Awiqli® (n=492) vs. glargine U100 (n=492), and in ONWARDS 3: Awiqli® (n=294) vs. degludec (n=294).1,3
Study participants were insulin-naïve patients with type 2 diabetes. Concomitant glucose-lowering agents were permitted from baseline throughout the study periods. In ONWARDS 1, sulphonylureas and glinides were discontinued at randomisation. In ONWARDS 3, sulphonylureas and glinides, if used, were reduced by 50% at randomisation at the investigator’s discretion. A similar proportion of patients, 175 of 984 and 112 of 588 (18% and 19%), were treated with GLP-1 RAs in the glargine U100 and degludec comparisons, respectively.2,3
ONWARDS 1: Awiqli® (n=492) vs. glargine U100 (n=492). End of main phase at 52 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 1.64 [0.98 to 2.75]. End of trial at 83 weeks: clinically significant or severe - Awiqli® 0.30/PYE vs. glargine U100 0.16/PYE; ERR [95% CI], 1.63 [1.02 to 2.61].1,2
ONWARDS 3: Awiqli® (n=293) vs. degludec (n=294). End of trial (26-week treatment period + 5-week follow-up period) at 31 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 1.82 [0.87 to 3.80], p=0.11. End of treatment period at 26 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 3.12 [1.30 to 7.51], p=0.01.1,3
Awiqli® (insulin icodec). Summary of Product Characteristics. Novo Nordisk A/S. [June 2024].
Rosenstock J, et al. N Engl J Med 2023; 389:297–308.
Lingvay I, et al. JAMA 2023; 330:228–237.
Patient User Guide - Dose Check.
Dose Check Evidence-Based Titration Plans Reference Document.
The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.
The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of May 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.